Bayer completes pricing negotiations for Jivi Inj in KOR

Bayer’s hemophilia A treatment nears reimbursement

Retevmo fails reimb due to a breakdown of pricing negotiations...Cinqair starts negotaitions

Bayer’s hemophilia A treatment

Bayer’s s hemophilia A treatment ‘Jivi Inj (damoctocog alfa pegol)’ has come one step near to receiving reimbursement in Korea.

 

On the other hand, reimbursement discussions for Lilly Korea’s ‘Retevmo (selpercatinib)’ have returned to square one after the company failed to complete pricing negotiations for its RET targeted anticancer drug with the NHIS.

 

In addition, Teva-Handok started pricing negotiations for its antibody drug for asthma, ‘Cinqair (reslizumab)’ with the NHIS.

 

According to the industry on the 24th, the NHIS had updated the drug pricing negotiation status of new drugs on its webpage recently.

 

The drug pricing negotiations for Jivi Inj were found to have been completed.

 

In May, the drug was approved for reimbursement under the condition that it accepts a price below the amount evaluated by the Drug Reimbursement Evaluation Committee of the Health Insurance Review and Assessment Service.

 

Jivi Inj then initiated and completed drug pricing negotiations with the NHIS.

 

However, due to the timing of the agreement, the drug will be listed for reimbursement the month after the next, rather than next month.

 

Jivi Inj is indicated for use in previously treated adults and adolescents (12 years of age and older) with hemophilia A (congenital Factor VIII deficiency) as an on-demand treatment and control of bleeding episodes, for the perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes.

 

Another drug, Lilly’s Retevmo Cap, had failed to reach an agreement after completing pricing negotiations.

 

Retevmo passed the DREC review in May but was unable to close the gap in opinion with the NHIS during pricing negotiations without extending the negotiation period.

 

As such, the company would need to restart the reimbursement application process from scratch for reimbursement in Korea.

 

Retevmo is indicated for the treatment of ▲RET-mutated medullary thyroid cancer and ▲ RET fusion benign thyroid cancer.

 

Although the number of patients is small, the drug is used in RET-mutated patients with poor prognosis.

 

No drug for RET mutation has been approved for reimbursement in Korea yet.

 

Teva-Handok newly started pricing negotiations for the reimbursement of its antibody drug for asthma, ‘Cinqair Inj.’ Cinqair passed DREC review in July.

 

The drug is used to treat severe eosinophilic asthma.

 

As an interleukin-5 (IL-5) inhibitor, it has a new mechanism of action that reduces the levels of blood eosinophils, a type of white blood cell that is involved in the development of asthma exacerbation.

 

Roche failed to reach an agreement within the deadline for its spinal muscular atrophy (SMA) treatment 'Everysdi Dry Syrup (risdiplam)', which has been under negotiations since last June and extended its negotiation period.